Sernova Corp. (SEOVF)
USD 0.15
(2.67%)
USD 0.15
(2.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.59 Million CAD | 96.71% |
| 2022 | 4.87 Million CAD | 178.35% |
| 2021 | 1.75 Million CAD | 10.83% |
| 2020 | 1.58 Million CAD | 130.14% |
| 2019 | 686.82 Thousand CAD | 101.3% |
| 2018 | 341.2 Thousand CAD | -62.13% |
| 2017 | 901.06 Thousand CAD | 6.47% |
| 2016 | 846.27 Thousand CAD | 323.45% |
| 2015 | 199.85 Thousand CAD | -16.76% |
| 2014 | 240.08 Thousand CAD | 6.64% |
| 2013 | 225.14 Thousand CAD | 68.08% |
| 2012 | 133.95 Thousand CAD | 12.5% |
| 2011 | 119.06 Thousand CAD | -17.31% |
| 2010 | 143.99 Thousand CAD | 40.87% |
| 2009 | 102.22 Thousand CAD | -15.41% |
| 2008 | 120.84 Thousand CAD | 252.45% |
| 2007 | 34.28 Thousand CAD | -71.93% |
| 2006 | 122.15 Thousand CAD | -49.57% |
| 2005 | 242.23 Thousand CAD | 38.6% |
| 2004 | 174.78 Thousand CAD | -4.17% |
| 2003 | 182.39 Thousand CAD | -2.82% |
| 2002 | 187.67 Thousand CAD | -58.07% |
| 2001 | 447.62 Thousand CAD | 233.85% |
| 2000 | 134.08 Thousand CAD | 0.0% |
| 1999 | - CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 20 Million CAD | 15.84% |
| 2024 Q1 | 14.73 Million CAD | 53.65% |
| 2024 Q2 | 17.26 Million CAD | 17.17% |
| 2023 Q4 | 9.59 Million CAD | -3.45% |
| 2023 Q1 | 6.42 Million CAD | 31.78% |
| 2023 Q3 | 9.93 Million CAD | 68.12% |
| 2023 Q2 | 5.9 Million CAD | -8.04% |
| 2023 FY | 9.59 Million CAD | 96.71% |
| 2022 Q4 | 4.87 Million CAD | 92.45% |
| 2022 Q1 | 2.26 Million CAD | 29.48% |
| 2022 FY | 4.87 Million CAD | 178.35% |
| 2022 Q2 | 2.9 Million CAD | 28.27% |
| 2022 Q3 | 2.53 Million CAD | -12.92% |
| 2021 Q4 | 1.75 Million CAD | 61.15% |
| 2021 Q2 | 1.31 Million CAD | 49.04% |
| 2021 FY | 1.75 Million CAD | 10.83% |
| 2021 Q1 | 881.71 Thousand CAD | -44.22% |
| 2021 Q3 | 1.08 Million CAD | -17.27% |
| 2020 Q2 | 992.24 Thousand CAD | 110.24% |
| 2020 FY | 1.58 Million CAD | 130.14% |
| 2020 Q1 | 471.96 Thousand CAD | -31.28% |
| 2020 Q3 | 1.42 Million CAD | 43.65% |
| 2020 Q4 | 1.58 Million CAD | 10.9% |
| 2019 FY | 686.82 Thousand CAD | 101.3% |
| 2019 Q4 | 686.82 Thousand CAD | 145.0% |
| 2019 Q3 | 280.34 Thousand CAD | -50.84% |
| 2019 Q2 | 570.25 Thousand CAD | 70.9% |
| 2019 Q1 | 333.68 Thousand CAD | -2.2% |
| 2018 Q1 | 567.45 Thousand CAD | -37.02% |
| 2018 Q3 | 489.2 Thousand CAD | -4.44% |
| 2018 Q4 | 341.2 Thousand CAD | -30.25% |
| 2018 FY | 341.2 Thousand CAD | -62.13% |
| 2018 Q2 | 511.92 Thousand CAD | -9.79% |
| 2017 Q2 | 704.89 Thousand CAD | -5.92% |
| 2017 Q4 | 901.06 Thousand CAD | -17.66% |
| 2017 FY | 901.06 Thousand CAD | 6.47% |
| 2017 Q1 | 749.25 Thousand CAD | -11.46% |
| 2017 Q3 | 1.09 Million CAD | 55.25% |
| 2016 Q2 | 1.05 Million CAD | -11.28% |
| 2016 FY | 846.27 Thousand CAD | 323.45% |
| 2016 Q1 | 1.18 Million CAD | 492.2% |
| 2016 Q4 | 846.27 Thousand CAD | -22.99% |
| 2016 Q3 | 1.09 Million CAD | 4.66% |
| 2015 Q3 | 163.04 Thousand CAD | -33.72% |
| 2015 Q1 | 144.3 Thousand CAD | -39.89% |
| 2015 Q2 | 245.98 Thousand CAD | 70.46% |
| 2015 FY | 199.85 Thousand CAD | -16.76% |
| 2015 Q4 | 199.85 Thousand CAD | 22.58% |
| 2014 Q2 | 182.17 Thousand CAD | -3.13% |
| 2014 FY | 240.08 Thousand CAD | 6.64% |
| 2014 Q3 | 223.78 Thousand CAD | 22.84% |
| 2014 Q4 | 240.08 Thousand CAD | 7.28% |
| 2014 Q1 | 188.05 Thousand CAD | -16.47% |
| 2013 Q4 | 225.14 Thousand CAD | 76.39% |
| 2013 Q3 | 127.64 Thousand CAD | -30.74% |
| 2013 Q2 | 184.3 Thousand CAD | 28.13% |
| 2013 Q1 | 143.83 Thousand CAD | 7.38% |
| 2013 FY | 225.14 Thousand CAD | 68.08% |
| 2012 FY | 133.95 Thousand CAD | 12.5% |
| 2012 Q2 | 163.06 Thousand CAD | 16.68% |
| 2012 Q4 | 133.95 Thousand CAD | 4.17% |
| 2012 Q3 | 128.59 Thousand CAD | -21.14% |
| 2012 Q1 | 139.75 Thousand CAD | 17.38% |
| 2011 FY | 119.06 Thousand CAD | -17.31% |
| 2011 Q1 | 136.75 Thousand CAD | -5.03% |
| 2011 Q2 | 101.53 Thousand CAD | -25.76% |
| 2011 Q3 | 91.34 Thousand CAD | -10.03% |
| 2011 Q4 | 119.06 Thousand CAD | 30.34% |
| 2010 FY | 143.99 Thousand CAD | 40.87% |
| 2010 Q1 | 50.25 Thousand CAD | -50.84% |
| 2010 Q2 | 64.03 Thousand CAD | 27.42% |
| 2010 Q4 | 143.99 Thousand CAD | 28.88% |
| 2010 Q3 | 111.72 Thousand CAD | 74.48% |
| 2009 Q1 | 66.25 Thousand CAD | -45.17% |
| 2009 Q4 | 102.22 Thousand CAD | 202.58% |
| 2009 Q3 | 33.78 Thousand CAD | -18.18% |
| 2009 FY | 102.22 Thousand CAD | -15.41% |
| 2009 Q2 | 41.28 Thousand CAD | -37.68% |
| 2008 Q4 | 120.84 Thousand CAD | -9.1% |
| 2008 Q3 | 132.93 Thousand CAD | -17.31% |
| 2008 Q2 | 160.77 Thousand CAD | 1457.74% |
| 2008 Q1 | 10.32 Thousand CAD | -69.9% |
| 2008 FY | 120.84 Thousand CAD | 252.45% |
| 2007 Q3 | 38.23 Thousand CAD | -79.75% |
| 2007 Q1 | 58.8 Thousand CAD | -51.86% |
| 2007 Q4 | 34.28 Thousand CAD | -10.32% |
| 2007 FY | 34.28 Thousand CAD | -71.93% |
| 2007 Q2 | 188.78 Thousand CAD | 221.03% |
| 2006 Q3 | 68.5 Thousand CAD | 6.61% |
| 2006 Q4 | 122.15 Thousand CAD | 78.31% |
| 2006 FY | 122.15 Thousand CAD | -49.57% |
| 2006 Q1 | 293.29 Thousand CAD | 21.08% |
| 2006 Q2 | 64.26 Thousand CAD | -78.09% |
| 2005 Q1 | 153.34 Thousand CAD | -12.26% |
| 2005 Q2 | 142.93 Thousand CAD | -6.79% |
| 2005 FY | 242.23 Thousand CAD | 38.6% |
| 2005 Q3 | 191.45 Thousand CAD | 33.94% |
| 2005 Q4 | 242.23 Thousand CAD | 26.53% |
| 2004 Q4 | 174.78 Thousand CAD | -38.35% |
| 2004 Q2 | 524.51 Thousand CAD | 67.21% |
| 2004 FY | 174.78 Thousand CAD | -4.17% |
| 2004 Q1 | 313.69 Thousand CAD | 71.99% |
| 2004 Q3 | 283.49 Thousand CAD | -45.95% |
| 2003 Q4 | 182.39 Thousand CAD | -10.61% |
| 2003 Q1 | 164.64 Thousand CAD | -12.27% |
| 2003 Q3 | 204.03 Thousand CAD | 26.52% |
| 2003 FY | 182.39 Thousand CAD | -2.82% |
| 2003 Q2 | 161.26 Thousand CAD | -2.05% |
| 2002 Q2 | 133.73 Thousand CAD | -37.32% |
| 2002 Q3 | 154.95 Thousand CAD | 15.86% |
| 2002 Q4 | 187.67 Thousand CAD | 21.12% |
| 2002 Q1 | 213.36 Thousand CAD | 0.0% |
| 2002 FY | 187.67 Thousand CAD | -58.07% |
| 2001 FY | 447.62 Thousand CAD | 233.85% |
| 2000 FY | 134.08 Thousand CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Qrons Inc. | 1.48 Million USD | -544.334% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 83.746% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1085.998% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -4669.526% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 80.916% |
| BioStem Technologies, Inc. | 15.9 Million USD | 39.689% |
| CSL Limited | 18.62 Billion USD | 99.948% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1.335% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 86.764% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 87.197% |
| Regen BioPharma, Inc. | 5.45 Million USD | -75.76% |
| Skye Bioscience, Inc. | 14.07 Million USD | 31.835% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -21361.16% |
| Rebus Holdings, Inc. | 5.24 Million USD | -82.989% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -34866.209% |
| Neon Bloom, Inc. | 1.22 Million USD | -682.269% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 82.005% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -0.107% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2175.381% |
| SQZ Biotechnologies Company | 50.03 Million USD | 80.83% |
| Intellipharmaceutics International Inc. | 12 Million USD | 20.123% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -149.058% |
| Mesoblast Limited | 188.44 Million USD | 94.91% |
| Marizyme, Inc. | 26.67 Million USD | 64.041% |
| Genus plc | 485 Million USD | 98.022% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -64.178% |
| Pharming Group N.V. | 244.07 Million USD | 96.07% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -377.197% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -281.201% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -152.428% |
| ContraFect Corporation | 32.53 Million USD | 70.513% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -384.139% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -150.605% |
| IMV Inc. | 37.93 Million USD | 74.712% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 18.559% |
| MultiCell Technologies, Inc. | 1617.67 USD | -592868.9% |
| ONE Bio Corp. | 27.49 Million USD | 65.114% |
| Accustem Sciences Inc. | 1.07 Million USD | -788.8% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 87.61% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -353.521% |
| Q BioMed Inc. | 8.13 Million USD | -17.944% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 88.434% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -86.401% |
| Biomind Labs Inc. | 1.49 Million USD | -540.078% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 91.92% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -6.084% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 47.878% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -568.983% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -6650.611% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -66.944% |
| GB Sciences, Inc. | 5.41 Million USD | -77.059% |
| Alpha Cognition Inc. | 7.16 Million USD | -33.881% |
| HST Global, Inc. | 593.59 Thousand USD | -1515.969% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -661.78% |
| Halberd Corporation | 728.71 Thousand USD | -1216.321% |
| Enzolytics Inc. | 365.26 Million USD | 97.374% |
| Agentix Corp. | 2.51 Million USD | -282.078% |
| Resverlogix Corp. | 67.39 Million USD | 85.767% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1043.664% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 97.844% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -459.643% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 61.237% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 19.414% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -161.715% |
| AVAX Technologies, Inc. | 3.99 Million USD | -140.183% |
| Zenith Capital Corp. | 27.56 Thousand USD | -34693.718% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.277% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3919.325% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -156.869% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1308.901% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -253.744% |
| Kadimastem Ltd | 3.5 Million USD | -173.685% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -14232.023% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1964.192% |
| LadRx Corporation | 2.2 Million USD | -335.908% |
| Cell Source, Inc. | 15.8 Million USD | 39.315% |
| Regen BioPharma, Inc. | 5.45 Million USD | -75.76% |
| NovAccess Global Inc. | 7.86 Million USD | -22.028% |
| Affymax, Inc. | 8.87 Million USD | -8.131% |
| Itoco Inc. | 1.65 Million USD | -480.242% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -367.559% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -58.576% |
| Mobile Lads Corp. | 1.31 Million USD | -630.286% |
| CytoDyn Inc. | 127.89 Million USD | 92.5% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -22848.587% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -512.386% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 13.155% |
| SYBLEU INC | 681.41 Thousand USD | -1307.704% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -57.201% |
| International Stem Cell Corporation | 5.27 Million USD | -81.775% |
| Bioxytran, Inc. | 3.24 Million USD | -195.192% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1432.781% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -107.754% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 76.602% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 56.918% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -373.602% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -75.106% |
| Neutra Corp. | 973.52 Thousand USD | -885.31% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 66.94% |
| PureTech Health plc | 125.58 Million USD | 92.362% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -155.309% |
| IXICO plc | 1.9 Million USD | -404.779% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 53.274% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 90.716% |
| CSL Limited | 18.62 Billion USD | 99.948% |
| Cellectis S.A. | 249.36 Million USD | 96.153% |